Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 23 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Zagouri, Flora [Clear All Filters]
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020). Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?.
Cancer Immunol Immunother.
(2020). The Role of CXCL13 and CXCL9 in Early Breast Cancer..
Clin Breast Cancer. 20(1), e36-e53.
(2020). Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer..
Cancer Genomics Proteomics. 17(2), 181-193.
(2020). Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer..
Cancer Genomics Proteomics. 16(3), 195-206.
(2019).
(2018).
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group..
J Transl Med. 15(1), 30.
(2017). The fate of BRCA1-related germline mutations in triple-negative breast tumors..
Am J Cancer Res. 7(1), 98-114.
(2017). Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers..
Cancer Genomics Proteomics. 14(3), 181-195.
(2017). Protein expression patterns of cell cycle regulators in operable breast cancer..
PLoS One. 12(8), e0180489.
(2017). Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study..
PLoS One. 11(10), e0164013.
(2016). Disease evolution and heterogeneity in bilateral breast cancer..
Am J Cancer Res. 6(11), 2611-2630.
(2016). Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes..
Breast Cancer Res Treat. 158(2), 307-21.
(2016). Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer..
Anticancer Res. 36(5), 2365-78.
(2016). TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting..
Oncotarget. 7(22), 32731-53.
(2016).
(2016).
(2016). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015).
(2015).
(2015). The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping..
Breast. 23(3), 234-43.
(2014). Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer..
Clin Breast Cancer. 14(5), 330-8.
(2014).